Rapamycin in aging and disease: Maximizing efficacy while minimizing side effects

Oncotarget

Volumn 7, Issue 29, 2016, Pages 44876-44878

  Johnson, Simon C ^a   Kaeberlein, Matt ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Healthspan; Mitochondria; Mitochondria disease; mTOR; Target of rapamycin

Indexed keywords

CHOLESTEROL; RAPAMYCIN; TRIACYLGLYCEROL;

AGING; ARTICLE; DRUG EFFICACY; DRUG SAFETY; ENCAPSULATION; GRAFT REJECTION; HUMAN; LEIGH DISEASE; LIFE EXTENSION; LONGEVITY; NONHUMAN; SEX DIFFERENCE; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; WOUND HEALING IMPAIRMENT; ANIMAL; DRUG EFFECTS; MOUSE;

AGING; ANIMALS; HUMANS; MICE; SIROLIMUS;

EID: 84979928345     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10381     Document Type: Article

References (10)

1. Johnson SC, Rabinovitch PS and Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature. 2013; 493:338-345.
2. Blagosklonny MV. Rejuvenating immunity: "anti-aging drug today" eight years later. Oncotarget. 2015; 6:19405-19412 doi: 10.18632/oncotarget.3740.
3. Kaeberlein M. The Biology of Aging: Citizen Scientists and Their Pets as a Bridge Between Research on Model Organisms and Human Subjects. Vet Pathol. 2016; 53:291-298.
4. Kaeberlein M. mTOR Inhibition: From Aging to Autism and Beyond. Scientifica (Cairo). 2013; 2013:849186.
5. Wilkinson JE, Burmeister L, Brooks SV, Chan CC, Friedline S, Harrison DE, Hejtmancik JF, Nadon N, Strong R, Wood LK, Woodward MA and Miller RA. Rapamycin slows aging in mice. Aging Cell. 2012; 11:675-682.
6. Miller RA, Harrison DE, Astle CM, Fernandez E, Flurkey K, Han M, Javors MA, Li X, Nadon NL, Nelson JF, Pletcher S, Salmon AB, Sharp ZD, Van Roekel S, Winkleman L and Strong R. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell. 2014; 13:468-477.
7. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Rosenfeld SV and Blagosklonny MV. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle. 2011; 10:4230-4236.
8. Arriola Apelo SI, Pumper CP, Baar EL, Cummings NE and Lamming DW. Intermittent Administration of Rapamycin Extends the Life Span of Female C57BL/6J Mice. J Gerontol A Biol Sci Med Sci. 2016; 71:876-81. doi: 10.1093/gerona/glw064.
9. Johnson SC, Yanos ME, Kayser EB, Quintana A, Sangesland M, Castanza A, Uhde L, Hui J, Wall VZ, Gagnidze A, Oh K, Wasko BM, Ramos FJ, Palmiter RD, Rabinovitch PS, Morgan PG, et al. mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome. Science. 2013; 342:1524-1528.
10. Johnson SC, Yanos ME, Bitto A, Castanza A, Gagnidze A, Gonzalez B, Gupta K, Hui J, Jarvie C, Johnson BM, Letexier N, McCanta L, Sangesland M, Tamis O, Uhde L, Van Den Ende A, et al. Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice. Frontiers in genetics. 2015; 6:247.